PS 02-06 Could be effective the use of Ranolazine for the treatment of refractory angina?

    loading  Checking for direct PDF access through Ovid



This study describes the use of ranolazine (R) for the treatment in patient (P) with chronic stable angina refractory (SAR) to maximal medical treatment.

Design and Method:

48 P, 56 y aged, were identified. All P had prior percutaneous coronary intervention and/or coronary artery bypass graft surgery. P with SAR who were receiving standard therapy with beta blockers or calcium antagonists or ace inhibitors were randomized to placebo or R 500mg twice daily, or R 750 mg twice daily.


After 24weeks (w) R group P had a 26% increase in total exercise time (P = .03) and a decrease in anginal episodes / w. The time to onset of 1 mm of ST-segment depression during exercise testing did not change. P in the treatment with R also had an increase in the QT interval. Pre R , antianginal use consisted of beta blockers (98%), long-acting nitrates (79%) and calcium channel blockers (41%). Median blood pressure (124.2/73.8 mmHg) and pulse (63bpm) were controlled. Median pre R angina episodes and sublingual nitroglycerin (SLNTG) doses / w were 21 and 14, respectively, with CCS angina grade of III–IV in 63% of P. After R, median angina episodes / w and SLNTG doses used / w decreased to 0.3 and 0, respectively, with CCS grade of III–IV declining to 22%. 41 P had complete resolution of angina episodes. Treatment with R resulted in a 24- to 56-second improvement in exercise tolerance (P < .001) in P who took 500 to 1500 mg of R twice daily.


The addition of R to maximally tolerated conventional antianginal drug therapy post coronary revascularization was associated with decreases in angina episodes and SLNTG utilization and improvement in CCS angina grades. R may provide an effective treatment option for revascularized P with SAR. R should be seen complementary to medical and interventional therapy of angina.

Related Topics

    loading  Loading Related Articles